Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/ Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell LymphomaAndré Goy, Ernest Richards, Themba Nyirenda et al.|Blood|2017Cited by 1
Interim or End of Treatment FGD-PET Complete Response Does Not Have Adequate Predictive Value in Mature T/NK Cell LymphomaTatyana Feldman, André Goy, Larysa Sanchez et al.|Blood|2016Cited by 0